A Costly Cure: Understanding and Addressing Financial Toxicity in Cardiovascular Disease Health Care Within the Domain of Social Determinants of Health

Methodist DeBakey Cardiovascular Journal, Год журнала: 2024, Номер 20(5), С. 15 - 26

Опубликована: Янв. 1, 2024

Cardiovascular disease (CVD) represents a significant financial burden on patients and families, compounded by both direct indirect healthcare costs. The increasing prevalence of CVD, coupled with the rising costs treatment, exacerbates toxicity-defined as economic strain associated physical, emotional, behavioral consequences patients. This review explores scope toxicity in CVD care, detailing its prevalence, risk factors, complex interplay social determinants health such income, insurance status, comorbidities. Drawing from models oncology, we highlight key interventions aimed at mitigating toxicity, including patient counseling, navigation, enhanced patient-physician cost discussions. By adopting these approaches, providers can better support managing their well-being, potentially improving clinical outcomes. Future research is needed to develop standardized assessment tools for implement system-wide mitigation strategies.

Язык: Английский

---

The Inflation Reduction Act Expands Prescription Drug Affordability

Journal of the American College of Cardiology, Год журнала: 2023, Номер 81(21), С. 2112 - 2114

Опубликована: Май 1, 2023

Язык: Английский

---

Economic and Ethical Case for Eliminating Patient Out-of-Pocket Costs

Circulation Cardiovascular Quality and Outcomes, Год журнала: 2023, Номер 16(10)

Опубликована: Окт. 1, 2023

Язык: Английский

---

Trends in Healthcare Expenditures and Incremental Healthcare Cost in Adults with Atrial Fibrillation in the United States

Heart Rhythm O2, Год журнала: 2024, Номер 6(1), С. 11 - 20

Опубликована: Окт. 21, 2024

Atrial fibrillation (AF) is associated with increased health care costs; however, comprehensive data on the financial burden of AF remain limited. The purpose this study was to delineate expenditures among patients AF. We used longitudinal panels from Medical Expenditure Panel Survey covering 2016-2019 estimate identified individuals 18 years and older in first year each panel (2016-2018) by using International Classification Disease, Tenth Revision codes. Covariates included sociodemographic characteristics comorbidities. Health were derived second (2017-2019) reflect cost having condition for an entire year. Adjusted mean annual costs calculated, including total expenditure, hospital inpatient, emergency department visits, office-based outpatient home prescribed medicines, other expenses. models incremental weighted population 3,080,055 adults (382 respondents; age 71.5; 89.9% white). adjusted totaled $14,083 (95% confidence interval $10,887-$17,279) compared $8771 $8106-$9436) those without primary drivers over time inpatient care, medications. $5312 per adult (in 2019 U.S. dollars). Adults United States face a higher across various services than do condition, consistently increasing expenses medicines. Further research needed identify independent contribution these costs.

Язык: Английский

---

President's page: The impact of the inflation reduction act on cardiovascular disease prevention

American Journal of Preventive Cardiology, Год журнала: 2023, Номер 15, С. 100591 - 100591

Опубликована: Сен. 1, 2023

Язык: Английский

---

The Inflation Reduction Act and Access to Heart Failure Therapies: Prices, Progress and Promise

Journal of Cardiac Failure, Год журнала: 2024, Номер 30(12), С. 1657 - 1658

Опубликована: Май 19, 2024

Язык: Английский

---

Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis

JACC Heart Failure, Год журнала: 2024, Номер 12(10), С. 1791 - 1793

Опубликована: Авг. 7, 2024

Язык: Английский

---

Tafamidis and the Paradox of Rare Disease Therapies

JAMA Network Open, Год журнала: 2024, Номер 7(9), С. e2427219 - e2427219

Опубликована: Сен. 13, 2024

Язык: Английский

---

The Price of ED: Annual Out of Pocket Cost Disparities of Erectile Dysfunction Medications

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Окт. 24, 2024

Our objective was to understand the out-of-pocket (OOP) annual costs for PDE5-I treat erectile dysfunction (ED) through traditional Medicare Part D drug coverage programs and other popular discount programs. We collected data on OOP ED medications from four different sources: D, GoodRx, Mark Cuban Cost Plus Drug Company (MCCPDC), Amazon Pharmacy. compared cost of lowest highest routinely prescribed dosage Sildenafil, Tadalafil, Vardenafil. examined under at 1) hospital retail pharmacies (using twelve zip codes encompassing areas with comprehensive urologic oncology centers) 2) three most prevalent commercial (CVS, Walgreens, Walmart). These findings were platforms GoodRx (via CVS, Walmart), MCCPDC, Pharmacy using R (V4.1.1). For Sildenafil 20mg, including hospitals comparable ranging $1 024-$1 098. The cheaper, $82-$275. 100mg, hospital-based had a median price 446, whereas ranged $22 528-$22 542. Discount preferred $89-$324. Tadalafil 2.5mg, groups $4 721-$4 759. this via much lower, $82-$312. $25 210-$25 235. reported have lower $103-$496. Vardenafil $19 015-$19 039 $86-418 platforms. both sildenafil dosages tadalafil dosages, MCCPDC affordable option. There are significant cost-savings when utilizing options should be presented patients help improve accessibility compliance ED.

Язык: Английский

---

The Inflation Reduction Act and Patient Costs for Drugs to Treat Heart Failure

JAMA Network Open, Год журнала: 2024, Номер 7(10), С. e2441915 - e2441915

Опубликована: Окт. 29, 2024

This cross-sectional study examines the pre–Inflation Reduction Act out-of-pocket burden on Medicare patients taking dapagliflozin, empagliflozin, and sacubitril/valsartan.

Язык: Английский

---